Upcoming seminar: Dr Cara Adolph: Department of Microbiology and Immunology
All roads lead to succinate: Attacking the energetic-metabolic hub of Mycobacterium tuberculosis to produce new antimicrobials.
Tuberculosis (TB) is a leading cause of infectious disease morbidity and mortality for which new antimicrobials are urgently required.
Mycobacterial energy metabolism has emerged as a particularly promising target space for antitubercular drug development. Succinate dehydrogenase (SDH) is a major focal point in mycobacterial energy metabolism and is essential for growth and survival in M. tuberculosis under a number of conditions, highlighting the potential of inhibitors targeting mycobacterial SDH enzymes.
In this seminar, I will discuss our recent work to advance SDH as a novel drug target in M. tuberculosis through the identification and characterisation of mycobacterial SDH inhibitors.